Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure

Strey, C; Young, Joanna M.; Molyneux, Sarah L.; George, Peter M.; Florkowski, Christopher M; Scott, Russell S.; Frampton, Christopher

doi:10.1016/j.atherosclerosis.2004.10.009

Cited by 84 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5] Statin therapy lowers morbidity and mortality in a broad range of patient populations with and without cardiovascular disease. [6][7][8][9][10] Statin therapy may also reduce the risk of HF, although patients with symptomatic and severe HF generally have been excluded from these studies.…”

Section: Administration Of Angiotensin-converting-enzyme (Ace) Inhibimentioning

confidence: 99%

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

SUMMARYHMG-CoA reductase inhibitors (statins) have recently been reported to improve cardiac function, and decrease the incidence of heart failure (HF) in hyperlipidemic patients. However, evidence for statin treatment in patients with HF remains a subject of debate. Thus, a study was initiated to examine the effects of pitavastatin on cardiac function evaluated by echocardiographic findings and plasma brain natriuretic peptide (BNP) levels in patients with HF. Twenty-three patients with HF were treated with pitavastatin 1-2 mg/ day in addition to standard therapy for 7.5 ± 3.8 months. Left ventricular end-diastolic dimension (LVDd) and left ventricular end-systolic dimension (LVDs) were determined by echocardiography. Left ventricular ejection fraction (LVEF) was calculated using Teichholz's formula. Serum lipid and plasma BNP levels were also measured. During the follow-up period, LVEF was increased from 42 ± 11 to 48 ± 13% (P = 0.002). LVDs was reduced from 43 ± 10 to 40 ± 10 mm (P < 0.001), while there was no change in LVDd. E/A (n = 10) and deceleration time (n = 7), obtained in some patients, did not change significantly (0.89 ± 0.33 to 0.77 ± 0.17%, and 215 ± 46 to 227 ± 72 msec, respectively). In addition, the plasma BNP level was moderately, but significantly decreased from 94 ± 78 to 70 ± 56 pg/mL (P = 0.005). In subgroup analysis, LVEF was improved in both patients with ischemic and nonischemic HF. There was no significant correlation between the percent change in serum total cholesterol and the percent change in LVEF by pitavastatin treatment. Serum total cholesterol, LDL-cholesterol, and triglycerides decreased by 21%, 30%, and 15%, respectively, and HDL-cholesterol increased by 12%. Pitavastatin improved cardiac function in patients with HF, which generally worsens with time. The results suggest that pitavastatin may be beneficial for treatment of HF. (Int Heart J 2008; 49: 49-58)

show abstract

Section: Administration Of Angiotensin-converting-enzyme (Ace) Inhibimentioning

confidence: 99%

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

show abstract

“…34 Short-term statin therapy also has been shown to improve endothelial function in chronic HF patients, even after adjustment for cholesterol level. 35,36 Although this is the largest study to date to assess the impact of statin therapy in a nationally representative cohort of older patients hospitalized with HF, there are outstanding issues to consider. This study was an observational study and does not have the strength of a randomized clinical trial, so its conclusions should be handled with important reservations.…”

Section: Foody Et Al Statins and Mortality In Heart Failurementioning

confidence: 99%

Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure

et al. 2006

View full text Add to dashboard Cite

Background— Small studies suggest that statins may improve mortality in patients with heart failure (HF). Whether these results are generalizable to a broader group of patients with HF remains unclear. Our objective was to evaluate the association between statin use and survival among a national sample of elderly patients hospitalized with HF. Methods and Results— A nationwide sample of 61 939 eligible Medicare beneficiaries ≥65 years of age who were hospitalized with a primary discharge diagnosis of HF between April 1998 and March 1999 or July 2000 and June 2001 was evaluated. The analysis was restricted to patients with no contraindications to statins (n=54 960). Of these patients, only 16.7% received statins on discharge. Older patients were less likely to receive a statin at discharge. Patients with hyperlipidemia and those cared for by a cardiologist or cared for in a teaching hospital were more likely to receive a statin at discharge. In a Cox proportional hazards model that took into account demographic, clinical characteristics, treatments, physician specialty, and hospital characteristics, discharge statin therapy was associated with significant improvements in 1- and 3-year mortality (hazard ratio, 0.80; 95% CI, 0.76 to 0.84; and hazard ratio, 0.82; 95% CI, 0.79 to 0.85, respectively). Regardless of total cholesterol level or coronary artery disease status, statin therapy was associated with significant differences in mortality. Conclusions— Our data demonstrate that statin therapy is associated with better long-term mortality in older patients with HF. This study suggests a potential role for statins as an adjunct to current HF therapy. Randomized clinical trials are required to determine the role of these agents in improving outcomes in the large and growing group of patients with HF.

show abstract

“…Jak wykazali Strey i wsp. [54], proces ten zachodzi u pacjentów z pozawieńcową HF. Udowodniono, że atorwastatyna w dawce 40 mg powodowała zmniejszenie stężenia CoQ 10 o 33% u chorych z pozawień-cową HF, choć nie przekreślało to poprawy funkcji śród-błonka [54].…”

Section: Jakie Są Konsekwencje Stosowaniaunclassified

“…[54], proces ten zachodzi u pacjentów z pozawieńcową HF. Udowodniono, że atorwastatyna w dawce 40 mg powodowała zmniejszenie stężenia CoQ 10 o 33% u chorych z pozawień-cową HF, choć nie przekreślało to poprawy funkcji śród-błonka [54]. Wystąpił również istotny związek (r = -0,585; p = 0,011) między zmniejszeniem CoQ 10 a poprawą czynności śródbłonka ocenianą za pomocą pletyzmografii na przedramieniu.…”

Section: Jakie Są Konsekwencje Stosowaniaunclassified